Clearside Biomedical, Inc. Forecast, price target & analysts
Clearside Biomedical, Inc. Target price 2025 - Analyst rating & recommendation
Clearside Biomedical, Inc. Classifications & Recommendation:
Clearside Biomedical, Inc. Price Target
| Target Price | $5.10 |
| Price | $0.77 |
| Potential |
562.34%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Clearside Biomedical, Inc. 2026 .
The average Clearside Biomedical, Inc. target price is $5.10.
This is
562.34%
register free of charge
$8.40
990.91%
register free of charge
$3.03
293.51%
register free of charge
|
|
| A rating was issued by 13 analysts: 12 Analysts recommend Clearside Biomedical, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Clearside Biomedical, Inc. stock has an average upside potential 2026 of
562.34%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 1.66 | 2.67 |
| 79.83% | 60.90% | |
| EBITDA Margin | -1,726.51% | -1,258.33% |
| 473.41% | 27.12% | |
| Net Margin | -2,069.28% | -1,230.89% |
| 424.17% | 40.52% |
9 Analysts have issued a sales forecast Clearside Biomedical, Inc. 2025 . The average Clearside Biomedical, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Clearside Biomedical, Inc. EBITDA forecast 2025. The average Clearside Biomedical, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Clearside Biomedical, Inc. Analysts have issued a net profit forecast 2025. The average Clearside Biomedical, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.47 | -0.43 |
| 11.32% | 8.51% | |
| P/E | negative | |
| EV/Sales | 17.30 |
9 Analysts have issued a Clearside Biomedical, Inc. forecast for earnings per share. The average Clearside Biomedical, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Clearside Biomedical, Inc....
Current Clearside Biomedical, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 23 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | May 16 2025 |
| Needham |
Locked
➜
Locked
|
Locked | May 15 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Apr 08 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
| Citizens Capital Markets |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 23 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
May 16 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
May 15 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Apr 08 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 28 2025 |
|
Locked
Citizens Capital Markets:
Locked
➜
Locked
|
Mar 28 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
